Evaluation of acute thrombus regression effect of anticoagulant for deep vein thrombosis in cancer patients

Evaluation of acute thrombus regression effect of anticoagulant for deep vein thrombosis in cancer patients - Evaluation of acute thrombus regression effect of anticoagulant for deep vein thrombosis in cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036958

Enrollment

Registered

2019-06-05

Start date

2019-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients who properly used Edoxaban followed by appropriate initial treatment (Heparin etc.) in the acute phase for deep vein thrombosis in cancer patients

Exclusion criteria

Exclusion criteria: 1 Patients who are contraindicated with heparin sodium and/or edoxaban 2 Patients judged as inappropriate by the research doctor

Design outcomes

Primary

Measure	Time frame
Thrombus regression effect from 7 to 14 days after initiation of anticoagulation therapy	—

Countries

Japan

Contacts

Public ContactShinji Hisatake

Toho Univaersity Omori Medical Center Department of Cardiovascular Medicine

s-hisata@td5.so-net.ne.jp03-3762-4151

Outcome results